HER2, HER3, and TROP2: An Update on Novel Treatments for Key Targets

Download All
Review the latest evidence on the optimal use of HER2, HER3, and TROP2 antibody–drug conjugates in breast, gastrointestinal, and lung cancers with an expert commentary plus a webcast with downloadable slides.
Aditya Bardia, MD, MPH
Program Director
Aditya Bardia, MD, MPH
Yelena Y. Janjigian, MD
Sandip P. Patel, MD

Downloadable Slidesets

Download these slides from a live symposium to learn more about targeting HER2, HER3, and TROP2 with antibody-drug conjugates in breast cancer.

Aditya Bardia, MD, MPH Released: April 8, 2022

Download these slides from a live symposium to learn more about targeting HER2 and TROP2 with antibody-drug conjugates in gastrointestinal cancers.

Yelena Y. Janjigian, MD Released: April 8, 2022

Download these slides from a live symposium to learn more about targeting HER2, HER3, and TROP2 with antibody-drug conjugates in non-small cell lung cancer.

Sandip P. Patel, MD Released: April 8, 2022

On Demand Webcast

In this on-demand webcast from a recent AACR satellite symposium, expert faculty highlight the latest evidence on the optimal use of HER2, HER3, and TROP2 antibody–drug conjugates in breast, gastrointestinal, and lung cancers.

Aditya Bardia, MD, MPH Yelena Y. Janjigian, MD Sandip P. Patel, MD Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: May 11, 2022 Expired: May 10, 2023

ClinicalThought

Commentary by physician experts in breast, gastrointestinal, and lung cancers on key takeaways from a live symposium on HER2-, HER3-, and TROP2-targeted therapies and treatment approaches for patients.

Aditya Bardia, MD, MPH
Program Director
Yelena Y. Janjigian, MD Sandip P. Patel, MD
Released: June 8, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings